{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:04:58Z","timestamp":1793444698566,"version":"4.5.0"},"reference-count":52,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The early thymic precursor (ETP) immunophenotype was previously reported to confer poor outcome in T-cell acute lymphoblastic leukemia (T-ALL). Between 2009 and 2014, 1256 newly diagnosed children and young adults enrolled in Children\u2019s Oncology Group (COG) AALL0434 were assessed for ETP status and minimal residual disease (MRD) using flow cytometry at a central reference laboratory. The subject phenotypes were categorized as ETP (n\u00a0= 145; 11.5%), near-ETP (n\u00a0= 209; 16.7%), or non-ETP (n\u00a0= 902; 71.8%). Despite higher rates of induction failure for ETP (6.2%) and near-ETP (6.2%) than non-ETP (1.2%; P\u00a0&amp;lt; .0001), all 3 groups showed excellent 5-year event-free survival (EFS) and overall survival (OS): ETP (80.4%\u00a0\u00b1 3.9% and 86.8\u00a0\u00b1 3.4%, respectively), near-ETP (81.1%\u00a0\u00b1 3.3% and 89.6%\u00a0\u00b1 2.6%, respectively), and non-ETP (85.3%\u00a0\u00b1 1.4% and 90.0%\u00a0\u00b1 1.2%, respectively; P\u00a0= .1679 and P\u00a0= .3297, respectively). There was no difference in EFS or OS for subjects with a day-29 MRD\u00a0&amp;lt;0.01% vs 0.01% to 0.1%. However, day-29 MRD \u22650.1% was associated with inferior EFS and OS for patients with near-ETP and non-ETP, but not for those with ETP. For subjects with day-29 MRD \u22651%, end-consolidation MRD \u22650.01% was a striking predictor of inferior EFS (80.9%\u00a0\u00b1 4.1% vs 52.4%\u00a0\u00b1 8.1%, respectively; P\u00a0= .0001). When considered as a single variable, subjects with all 3 T-ALL phenotypes had similar outcomes and subjects with persistent postinduction disease had inferior outcomes, regardless of their ETP phenotype. This clinical trial was registered at AALL0434 as #NCT00408005.<\/jats:p>","DOI":"10.1182\/blood.2023020678","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T19:05:29Z","timestamp":1691607929000},"page":"2069-2078","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study"],"prefix":"10.1182","volume":"142","author":[{"given":"Brent L.","family":"Wood","sequence":"first","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA"},{"name":"2Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-3478","authenticated-orcid":false,"given":"Meenakshi","family":"Devidas","sequence":"additional","affiliation":[{"name":"3Department of Global Pediatric Medicine, Saint Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3621-8664","authenticated-orcid":false,"given":"Ryan J.","family":"Summers","sequence":"additional","affiliation":[{"name":"4Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA"},{"name":"5Department of Pediatrics, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Chen","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Asselin","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-8195","authenticated-orcid":false,"given":"Karen R.","family":"Rabin","sequence":"additional","affiliation":[{"name":"8Pediatric Hematology\/Oncology, Baylor College of Medicine\/Dan L Duncan Comprehensive Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Zweidler-McKay","sequence":"additional","affiliation":[{"name":"9ImmunoGen Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6636-3870","authenticated-orcid":false,"given":"Naomi J.","family":"Winick","sequence":"additional","affiliation":[{"name":"10Pediatric Hematology and Oncology, UT Southwestern\/Simmons Cancer Center-Dallas, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Borowitz","sequence":"additional","affiliation":[{"name":"11Department of Pathology, Johns Hopkins University\/Sidney Kimmel Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Carroll","sequence":"additional","affiliation":[{"name":"12Department of Pediatrics and Pathology, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, Hassenfeld Children's Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Raetz","sequence":"additional","affiliation":[{"name":"13Division of Pediatric Hematology and Oncology, Department of Pediatrics, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[{"name":"14Ben Towne Center for Childhood Cancer Research, Seattle Children\u2019s Research Institute, Seattle, WA"},{"name":"15Department of Pediatrics, Seattle Children\u2019s Hospital, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[{"name":"16Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly P.","family":"Dunsmore","sequence":"additional","affiliation":[{"name":"17Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[{"name":"16Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart S.","family":"Winter","sequence":"additional","affiliation":[{"name":"18Cancer and Blood Disorders Program, Children\u2019s Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2023121416231680000_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.blre.2017.08.006","article-title":"T\u00a0cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies","volume":"32","author":"Vadillo","year":"2018","journal-title":"Blood Rev"},{"issue":"16","key":"2023121416231680000_bib2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"2023121416231680000_bib3","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023121416231680000_bib4","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group","volume":"30","author":"Hunger","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023121416231680000_bib5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<600::AID-CNCR24>3.0.CO;2-4","article-title":"Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features randomized controlled trial from the Children's Cancer Group","volume":"82","author":"Steinherz","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"2023121416231680000_bib6","first-page":"735","article-title":"Biology and treatment of childhood T-lineage acute lymphoblastic leukemia","volume":"91","author":"Uckun","year":"1998","journal-title":"Blood"},{"issue":"29","key":"2023121416231680000_bib7","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023121416231680000_bib8","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2023121416231680000_bib9","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1182\/blood.V99.12.4386","article-title":"Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL","volume":"99","author":"Willemse","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2023121416231680000_bib10","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1200\/JCO.1998.16.4.1270","article-title":"Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group","volume":"16","author":"Heerema","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023121416231680000_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"24","key":"2023121416231680000_bib12","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1200\/JCO.2010.28.3390","article-title":"Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia","volume":"28","author":"Gutierrez","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023121416231680000_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.2013.090233","article-title":"Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors","volume":"99","author":"Zuurbier","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"2023121416231680000_bib14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08955.x","article-title":"Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the\u00a0Tokyo Children's Cancer Study Group Study L99-15","volume":"156","author":"Inukai","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"2023121416231680000_bib15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ajh.26144","article-title":"Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine","volume":"96","author":"Morita","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"2023121416231680000_bib16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1084\/jem.162.3.802","article-title":"Early T lymphocytes. Differentiation in\u00a0vivo of adult intrathymic precursor cells","volume":"162","author":"Fowlkes","year":"1985","journal-title":"J\u00a0Exp Med"},{"issue":"12","key":"2023121416231680000_bib17","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1084\/jem.188.12.2301","article-title":"CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity","volume":"188","author":"Azzam","year":"1998","journal-title":"J\u00a0Exp Med"},{"issue":"7188","key":"2023121416231680000_bib18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nature06839","article-title":"Adult T-cell progenitors retain myeloid potential","volume":"452","author":"Wada","year":"2008","journal-title":"Nature"},{"issue":"4","key":"2023121416231680000_bib19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11684-012-0224-4","article-title":"Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia","volume":"6","author":"Ma","year":"2012","journal-title":"Front Med"},{"issue":"22","key":"2023121416231680000_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood.V114.22.9.9","article-title":"Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction\u2014a Children\u2019s Oncology Group (COG) study [abstract]","volume":"114","author":"Wood","year":"2009","journal-title":"Blood"},{"key":"2023121416231680000_bib21","first-page":"788","article-title":"Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia have high levels of minimal residual disease at the end of induction - a Children's Oncology Group (COG) study","volume":"56","author":"Loh","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2023121416231680000_bib22","doi-asserted-by":"crossref","first-page":"e28719","DOI":"10.1002\/pbc.28719","article-title":"Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL Consortium protocols 05-001 and 11-001","volume":"68","author":"Burns","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2023121416231680000_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12882","article-title":"Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"166","author":"Patrick","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"2023121416231680000_bib24","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(15)00254-9","article-title":"Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis","volume":"3","author":"Conter","year":"2016","journal-title":"Lancet Haematol"},{"issue":"28","key":"2023121416231680000_bib25","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2023121416231680000_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434 [abstract]","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2023121416231680000_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cyto.b.20511","article-title":"Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection","volume":"78","author":"Roshal","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"2023121416231680000_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-62703-357-2_8","article-title":"Flow cytometric monitoring of residual disease in acute leukemia","volume":"999","author":"Wood","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"3","key":"2023121416231680000_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM198801213180307","article-title":"T-cell antigen deficiencies and clonal rearrangements of T-cell receptor genes in pagetoid reticulosis (Woringer-Kolopp disease)","volume":"318","author":"Wood","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023121416231680000_bib30","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41375-018-0039-7","article-title":"Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG)","volume":"32","author":"Gupta","year":"2018","journal-title":"Leukemia"},{"key":"2023121416231680000_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples","volume":"35","author":"Peto","year":"1977","journal-title":"Br J Cancer"},{"issue":"282","key":"2023121416231680000_bib32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"2023121416231680000_bib33","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"8","key":"2023121416231680000_bib34","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2023121416231680000_bib35","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.19.02892","article-title":"Impact of intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: Children's Oncology Group study AALL1131","volume":"38","author":"Salzer","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"2023121416231680000_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","article-title":"Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia","volume":"1","author":"Ferrando","year":"2002","journal-title":"Cancer Cell"},{"issue":"4","key":"2023121416231680000_bib37","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ccr.2011.02.008","article-title":"Integrated transcript and genome analyses\u00a0reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia","volume":"19","author":"Homminga","year":"2011","journal-title":"Cancer Cell"},{"issue":"7380","key":"2023121416231680000_bib38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"8","key":"2023121416231680000_bib39","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic\u00a0landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"issue":"11","key":"2023121416231680000_bib40","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2023121416231680000_bib41","first-page":"773","article-title":"14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia","volume":"138","author":"Di Giacomo","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2023121416231680000_bib42","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/bjh.17681","article-title":"B-cell lymphoma\/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia\/lymphoma (ETP-ALL\/LBL) from other subtypes of T-cell ALL\/LBL","volume":"194","author":"Fang","year":"2021","journal-title":"Br J Haematol"},{"key":"2023121416231680000_bib43","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/2159-8290.CD-21-0145","article-title":"Enhancer hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia","volume":"11","author":"Montefiori","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"2023121416231680000_bib44","doi-asserted-by":"crossref","first-page":"101329","DOI":"10.1016\/j.beha.2021.101329","article-title":"Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage","volume":"34","author":"Montefiori","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"2023121416231680000_bib45","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/leu.2016.60","article-title":"MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"30","author":"Matlawska-Wasowska","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"2023121416231680000_bib46","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"12","key":"2023121416231680000_bib47","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/leu.2017.136","article-title":"JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias","volume":"31","author":"Delgado-Martin","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2023121416231680000_bib48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI130189","article-title":"Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes","volume":"130","author":"Meyer","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"2023121416231680000_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.HS9.0000843304.00278.87","article-title":"Comprehensive genome characterization reveals new subtypes and mechanisms of oncogene deregulation in childhood T-ALL","volume":"6","author":"P\u00f6l\u00f6nen","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2023121416231680000_bib50","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood-2022-167157","article-title":"Comprehensive genome characterization of childhood T-ALL links oncogene activation mechanism and subtypes to prognosis [abstract]","volume":"140","author":"P\u00f6l\u00f6nen","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023121416231680000_bib51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2018-99-110221","article-title":"A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269\/AALL1521): dose-finding results from the part 1 safety phase [abstract]","volume":"132","author":"Tasian","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2023121416231680000_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-137376","article-title":"Pediatric patients with relapsed\/refractory acute lymphoblastic leukemia harboring heterogeneous genomic profiles respond to venetoclax in combination with chemotherapy [abstract]","volume":"136","author":"Place","year":"2020","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/24\/2069\/2176476\/blood_bld-2023-020678-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/24\/2069\/2176476\/blood_bld-2023-020678-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T16:23:59Z","timestamp":1702571039000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/24\/2069\/497401\/Prognostic-significance-of-ETP-phenotype-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":52,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020678","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]}}}